Schrödinger Unveils ‘Bunsen’ AI Co-Scientist to Accelerate End-to-End Biologics Discovery Workflow with BioLuminate and LiveDesign Integration

August 17, 2026

Schrödinger USA

Overview

Schrödinger is hosting an event to demonstrate an integrated, end-to-end workflow accelerating biologics discovery and engineering through BioLuminate and LiveDesign. A highlight of this session is the introduction of Schrödinger’s new AI Co-Scientist, ‘Bunsen,’ aiming to transform complex drug discovery into a seamless, automated workflow. Bunsen has the potential to streamline decision-making in biologics development, reducing both development timelines and costs.

In Depth

Key Findings

Schrödinger is set to showcase an integrated, end-to-end workflow designed to accelerate biologics discovery and engineering, combining its BioLuminate and LiveDesign platforms. The centerpiece of this announcement is the introduction of ‘Bunsen,’ Schrödinger’s newly developed AI Co-Scientist. Bunsen aims to revolutionize the complex drug discovery process into a seamlessly automated workflow, promising significant enhancements in the efficiency of biologics development. This represents a strategic leap in computational drug discovery platforms.

Technical / Clinical Details

Schrödinger’s integrated workflow accelerates biologics design and optimization by combining BioLuminate’s advanced modeling and simulation capabilities with LiveDesign’s real-time collaborative design platform. The AI Co-Scientist, Bunsen, acts as the core of this workflow, assisting researchers in hypothesis generation, experimental planning, and data analysis. For antibody design, for example, Bunsen provides AI-driven suggestions for simultaneously optimizing multiple parameters such as binding affinity, stability, and immunogenicity, thereby resolving bottlenecks from molecular design to preclinical evaluation. This empowers researchers to efficiently explore larger design spaces and rapidly identify promising candidates, reducing the iterative cycle of traditional methods.

Background & Context

Biologics offer groundbreaking therapies for a wide range of diseases, including cancer, autoimmune disorders, and infectious diseases. However, their discovery and development are exceptionally complex, time-consuming, and expensive. Traditional processes often require extensive trial-and-error, leading to low success rates. The advancement of AI technologies presents a transformative opportunity to overcome these challenges and dramatically improve the efficiency of biologics development. Schrödinger has positioned itself as a leader in this field by integrating its long-standing expertise in computational chemistry with cutting-edge AI technologies, setting new industry benchmarks.

Strategic Significance & Outlook

The introduction of the AI Co-Scientist ‘Bunsen’ and the integrated workflow holds the potential to transform the paradigm of biologics development. This technology is expected to allow drug discovery scientists to focus on more complex scientific questions, automating routine tasks, and thereby significantly shortening the time it takes to deliver new biologics to patients. In the future, Bunsen is anticipated to evolve further, supporting the design of novel modalities and offering optimization suggestions based on clinical trial data, contributing across the entire drug discovery pipeline. This will enable the pharmaceutical industry to develop innovative therapies more rapidly and cost-effectively, addressing global health challenges with unprecedented speed.

Source: https://www.schrodinger.com/life-science/resources/event/accelerating-biologics-discovery-an-end-to-end-workflow-with-bioluminate-and-livedesign/

Get our weekly technology intelligence — free

Receive an infographic that lets you judge at a glance whether each field’s analysis report is worth reading.

Subscribe Free — Weekly Tech Intelligence

By subscribing, you’ll receive Troy-Technical’s weekly technology intelligence newsletter.